122 related articles for article (PubMed ID: 8194887)
1. Immunotherapy with antibodies to the EGF receptor.
Dean C; Modjtahedi H; Eccles S; Box G; Styles J
Int J Cancer Suppl; 1994; 8():103-7. PubMed ID: 8194887
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.
Modjtahedi H; Eccles S; Box G; Styles J; Dean C
Br J Cancer; 1993 Feb; 67(2):254-61. PubMed ID: 7679281
[TBL] [Abstract][Full Text] [Related]
3. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.
Modjtahedi H; Styles JM; Dean CJ
Br J Cancer; 1993 Feb; 67(2):247-53. PubMed ID: 8094290
[TBL] [Abstract][Full Text] [Related]
4. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.
Modjtahedi H; Moscatello DK; Box G; Green M; Shotton C; Lamb DJ; Reynolds LJ; Wong AJ; Dean C; Thomas H; Eccles S
Int J Cancer; 2003 Jun; 105(2):273-80. PubMed ID: 12673691
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer.
Modjtahedi H; Hickish T; Nicolson M; Moore J; Styles J; Eccles S; Jackson E; Salter J; Sloane J; Spencer L; Priest K; Smith I; Dean C; Gore M
Br J Cancer; 1996 Jan; 73(2):228-35. PubMed ID: 8546911
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor.
Modjtahedi H; Eccles SA; Box G; Styles J; Dean CJ
Cell Biophys; 1993; 22(1-3):129-46. PubMed ID: 7534211
[TBL] [Abstract][Full Text] [Related]
7. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C
Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies.
Baselga J; Norton L; Masui H; Pandiella A; Coplan K; Miller WH; Mendelsohn J
J Natl Cancer Inst; 1993 Aug; 85(16):1327-33. PubMed ID: 8340945
[TBL] [Abstract][Full Text] [Related]
9. Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.
Modjtahedi H; Komurasaki T; Toyoda H; Dean C
Int J Cancer; 1998 Jan; 75(2):310-6. PubMed ID: 9462724
[TBL] [Abstract][Full Text] [Related]
10. The binding of HB-EGF to tumour cells is blocked by mAbs which act as EGF and TGF alpha antagonists.
Modjtahedi H; Dean C
Biochem Biophys Res Commun; 1995 Feb; 207(1):389-97. PubMed ID: 7857293
[TBL] [Abstract][Full Text] [Related]
11. The epidermal growth factor receptor as a target for therapy in breast carcinoma.
Baselga J; Mendelsohn J
Breast Cancer Res Treat; 1994 Jan; 29(1):127-38. PubMed ID: 8018961
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth.
Harwerth IM; Wels W; Schlegel J; Müller M; Hynes NE
Br J Cancer; 1993 Dec; 68(6):1140-5. PubMed ID: 7903153
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
[TBL] [Abstract][Full Text] [Related]
14. Expression of transforming growth factor alpha and its receptor in human neuroendocrine tumours.
Nilsson O; Wängberg B; Kölby L; Schultz GS; Ahlman H
Int J Cancer; 1995 Mar; 60(5):645-51. PubMed ID: 7860139
[TBL] [Abstract][Full Text] [Related]
15. The extracellular domain of the epidermal growth factor receptor. Studies on the affinity and stoichiometry of binding, receptor dimerization and a binding-domain mutant.
Brown PM; Debanne MT; Grothe S; Bergsma D; Caron M; Kay C; O'Connor-McCourt MD
Eur J Biochem; 1994 Oct; 225(1):223-33. PubMed ID: 7925442
[TBL] [Abstract][Full Text] [Related]
16. Role of transforming growth factor-alpha (TGF-alpha) in basal and hormone-stimulated growth by estradiol, prolactin and progesterone in human and rat mammary tumor cells: studies using TGF-alpha and EGF receptor antibodies.
Ahmed SR; Badger B; Wright C; Manni A
J Steroid Biochem Mol Biol; 1991 Jun; 38(6):687-93. PubMed ID: 2064983
[TBL] [Abstract][Full Text] [Related]
17. Differential role of transforming growth factor-alpha in two human colon-carcinoma cell lines.
Watkins LF; Levine AE
Int J Cancer; 1991 Feb; 47(3):455-60. PubMed ID: 1993555
[TBL] [Abstract][Full Text] [Related]
18. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
19. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5.
Modjtahedi H; Affleck K; Stubberfield C; Dean C
Int J Oncol; 1998 Aug; 13(2):335-42. PubMed ID: 9664130
[TBL] [Abstract][Full Text] [Related]
20. Growth effects of epidermal growth factor (EGF) and a monoclonal antibody against the EGF receptor on four glioma cell lines.
Werner MH; Humphrey PA; Bigner DD; Bigner SH
Acta Neuropathol; 1988; 77(2):196-201. PubMed ID: 3265834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
